n-methyl-3,4-methylenedioxyamphetamine has been researched along with Idiopathic Parkinson Disease in 12 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Drugs used for the treatment of Parkinson's disease and endocrine diseases, like hyperprolactinemia, may also induce VHD." | 2.49 | Drug-induced valvular heart disease. ( Cosyns, B; Droogmans, S; Lancellotti, P; Rosenhek, R, 2013) |
| "He had a family history of Parkinson's disease, though the onset of his symptoms was significantly earlier than those of his family members." | 1.91 | Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report. ( Guo, S; Hui, T, 2023) |
| " These data identify a new class of therapeutic in Parkinson's disease and highlight the potential benefits of studying illicit drugs that in themselves would never be considered safe for long-term therapy." | 1.38 | A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. ( Brotchie, JM; Fox, SH; Gandy, MN; Gomez-Ramirez, J; Huot, P; Johnston, TH; Lee, J; Lewis, KD; Martin-Iverson, M; McIldowie, M; Millar, Z; Nash, JE; Piggott, MJ; Salomonczyk, D; Thiele, S; Wagg, K; Yong-Kee, CJ, 2012) |
| " In a forward genetic screen, we identified a mutant resistant to the toxic effects of dopamine." | 1.37 | A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity. ( McIntire, SL; Schreiber, MA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, X | 1 |
| Li, S | 1 |
| Li, J | 1 |
| Qi, R | 1 |
| Zhong, L | 1 |
| Yu, H | 1 |
| Hui, T | 1 |
| Guo, S | 1 |
| Sgambato, V | 1 |
| Nichols, D | 1 |
| Schreiber, MA | 1 |
| McIntire, SL | 1 |
| Johnston, TH | 1 |
| Millar, Z | 1 |
| Huot, P | 1 |
| Wagg, K | 1 |
| Thiele, S | 1 |
| Salomonczyk, D | 1 |
| Yong-Kee, CJ | 1 |
| Gandy, MN | 1 |
| McIldowie, M | 1 |
| Lewis, KD | 1 |
| Gomez-Ramirez, J | 1 |
| Lee, J | 1 |
| Fox, SH | 1 |
| Martin-Iverson, M | 1 |
| Nash, JE | 1 |
| Piggott, MJ | 1 |
| Brotchie, JM | 1 |
| Cosyns, B | 1 |
| Droogmans, S | 1 |
| Rosenhek, R | 1 |
| Lancellotti, P | 1 |
| Lebsanft, HB | 1 |
| Mayerhofer, A | 1 |
| Kovar, KA | 1 |
| Schmidt, WJ | 1 |
| Holden, C | 1 |
| O'Suilleabhain, P | 1 |
| Giller, C | 1 |
| Morton, J | 1 |
| Cadet, JL | 1 |
| Brannock, C | 1 |
3 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Drug-induced valvular heart disease.
Topics: Dopamine Agonists; Ergolines; Global Health; Heart Valve Diseases; Humans; N-Methyl-3,4-methylenedio | 2013 |
Ecstasy: pharmacology and neurotoxicity.
Topics: Affect; Animals; Binding Sites; Brain; Fever; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamph | 2005 |
Free radicals and the pathobiology of brain dopamine systems.
Topics: Animals; Brain; Dopamine; Free Radicals; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyampheta | 1998 |
9 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson's disease progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; Dopaminergic Neurons; Humans; MicroRNAs; | 2023 |
Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.
Topics: Adult; Dopamine; Humans; Male; Methamphetamine; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; | 2023 |
Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
Topics: Animals; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Haplorhini; Humans; Levodopa; N | 2021 |
Legal highs: the dark side of medicinal chemistry.
Topics: Amphetamines; Animals; Depression; Designer Drugs; Drug Design; Electronic Mail; Hallucinogens; Huma | 2011 |
A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dopamine; Dopamine Agents; Immunit | 2011 |
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
Topics: Animals; Antiparkinson Agents; Benzodioxoles; Cell Line, Tumor; Drug Synergism; Levodopa; Male; Meth | 2012 |
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Citalopram | 2003 |
Retraction. Paper on toxic party drug is pulled over vial mix-up.
Topics: Animals; Dopamine; Drug Labeling; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; N | 2003 |
Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.
Topics: Adult; Antiparkinson Agents; Disease Progression; Hallucinogens; Hepatitis C; Humans; Indoles; Male; | 2003 |